{"drugs":["Bupivacaine Liposome","Exparel"],"mono":{"0":{"id":"930031-s-0","title":"Generic Names","mono":"Bupivacaine Liposome"},"1":{"id":"930031-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930031-s-1-4","title":"Adult Dosing","mono":"<ul><li>different formulations of bupivacaine are NOT bioequivalent and are not interchangeable; do not convert dosing on a mg-to-mg basis; do NOT substitute<\/li><li><b>Postoperative pain:<\/b> (bunionectomy) single-dose 106 mg (8 mL); INFILTRATE 7 mL into surrounding tissues of the osteotomy and 1 mL into the subcutaneous tissue (MAX 266 mg\/dose (20 mL, 1.3% of undiluted drug))<\/li><li><b>Postoperative pain:<\/b> (hemorrhoidectomy) single-dose 266 mg (20 mL); dilute 20 mL with 10 mL of NS for a total of 30 mL, divide into six 5-mL aliquots, visualize anal sphincter as a clock face, perform anal block by INFILTRATING slowly one aliquot to each of the even numbers (MAX 266 mg\/dose (20 mL, 1.3% of undiluted drug))<\/li><\/ul>"},"1":{"id":"930031-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children less than 18 years of age "},"3":{"id":"930031-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Postoperative pain<br\/>"}}},"3":{"id":"930031-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930031-s-3-9","title":"Contraindications","mono":"obstetrical paracervical block anesthesia <br\/>"},{"id":"930031-s-3-10","title":"Precautions","mono":"<ul><li>cardiac arrest have occurred with accidental intravascular injection of bupivacaine and amide-containing products<\/li><li>cardiovascular impairment; risk of reduced ability to compensate for functional changes associated with atrioventricular conduction prolongation; monitoring recommended<\/li><li>cardiovascular system reactions, serious and fatal (eg, decreased cardiac output and arterial blood pressure, atrioventricular block, ventricular arrhythmias, cardiac arrest), may occur with toxic concentrations; monitoring recommended<\/li><li>central nervous system excitation and\/or depression may occur with local anesthetics, possibly leading to convulsions, unconsciousness, or respiratory arrest; may be related to dose and particular anesthetic used, route, and physical status of patient; monitoring recommended<\/li><li>chondrolysis has been reported with intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures (unapproved use)<\/li><li>convulsions have occurred with accidental intravascular injection of bupivacaine and amide-containing products<\/li><li>hepatic disease, severe; increased risk of developing toxic plasma concentrations<\/li><li>hypersensitivity, including anaphylactoid-like symptoms, may occur; cross-sensitivity between amide-type local anesthetics has been reported<\/li><li>neurologic effects (eg, persistent anesthesia, paresthesias, weakness, paralysis) may occur with soft tissue infiltration<\/li><li>repeated injections; risk of significant increase in plasma concentrations<\/li><li>report suspected adverse reactions to US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930031-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930031-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"930031-s-4","title":"Drug Interactions","sub":{"1":{"id":"930031-s-4-14","title":"Major","mono":"<ul><li>Hyaluronidase (probable)<\/li><li>Propofol (probable)<\/li><li>Propranolol (probable)<\/li><li>St John's Wort (probable)<\/li><li>Verapamil (probable)<\/li><\/ul>"},"2":{"id":"930031-s-4-15","title":"Moderate","mono":"<ul><li>Alacepril (probable)<\/li><li>Benazepril (probable)<\/li><li>Captopril (probable)<\/li><li>Cilazapril (probable)<\/li><li>Delapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Enalapril Maleate (probable)<\/li><li>Fosinopril (probable)<\/li><li>Imidapril (probable)<\/li><li>Lisinopril (probable)<\/li><li>Moexipril (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Spirapril (probable)<\/li><li>Temocapril (probable)<\/li><li>Trandolapril (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"930031-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Tachycardia (3.9%)<\/li><li><b>Dermatologic:<\/b>Pruritus (3.1% to 5.2%)<\/li><li><b>Gastrointestinal:<\/b>Constipation (2.1%), Nausea (up to 40.2%), Vomiting (27.8%)<\/li><li><b>Neurologic:<\/b>Dizziness (6.2%), Headache (3.8%), Somnolence (up to 5.2%)<\/li><li><b>Other:<\/b>Fever (2.1%)<\/li><\/ul>"},"6":{"id":"930031-s-6","title":"Drug Name Info","sub":{"0":{"id":"930031-s-6-17","title":"US Trade Names","mono":"Exparel<br\/>"},"2":{"id":"930031-s-6-19","title":"Class","mono":"<ul><li>Amino Amide<\/li><li>Anesthetic, Local<\/li><\/ul>"},"3":{"id":"930031-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930031-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930031-s-7","title":"Mechanism Of Action","mono":"Bupivacaine liposome, is an amide local anesthetic in an encapsulated formulation which provides more persistent anesthetic action. Anesthesia is accomplished by an increasing in the nerve electrical excitation threshold, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential, all which block the generation and conduction of nerve impulses.<br\/>"},"8":{"id":"930031-s-8","title":"Pharmacokinetics","sub":[{"id":"930031-s-8-23","title":"Absorption","mono":"Tmax, Infiltration: 0.5 to 2 hours <br\/>"},{"id":"930031-s-8-24","title":"Distribution","mono":"Protein binding: 95% <br\/>"},{"id":"930031-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>Pipecolylxylidine: unknown<\/li><\/ul>"},{"id":"930031-s-8-26","title":"Excretion","mono":"Renal: 6% unchanged <br\/>"},{"id":"930031-s-8-27","title":"Elimination Half Life","mono":"23.8 to 34.1 hours <br\/>"}]},"9":{"id":"930031-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>Administer by infiltration only; do not administer epidurally, intrathecally, intravascularly, intra-articularly, or as a regional nerve block.<br\/><\/li><li><b>Injection<\/b><br\/><ul><li>Invert vials multiple times to resuspend the particles immediately prior to withdrawal from the vial.<\/li><li>Do not mix with lidocaine or other non-bupivacaine based local anesthetics.<\/li><li>Do not filter<\/li><li>Do not re-refrigerate vials; record the date on the vial when it has been removed from refrigeration.<\/li><li>Do not heat or autoclave before use.<\/li><li>Administer within 4 hours after withdrawal from vial; discard any unused portion.<\/li><li>May be administered undiluted or may be diluted up to 0.89 mg\/mL (ie, 1:14 dilution by volume) with NS or LR<\/li><li>Administer as a single-dose by infiltration only.<\/li><li>Inject slowly into soft tissues of the surgical site with frequent aspiration to check for blood and minimize the risk of intravascular injection.<\/li><li>May be administered after at least 20 minutes or more following administration of local lidocaine<\/li><li>Do not allow for contact with antiseptics, such as povidone iodine, in solution; allow injection site to be dried of such topical antiseptics prior to injection into the surgical site.<\/li><li>Use 25 gauge or larger bore needle.<\/li><li>Check temperature indicator of vials prior to administration; do not administer if the stopper is bulging, or if product has been exposed to high temperatures (greater than 40 degree C, or 104 degree F) for an extended period.<\/li><li>Do not administer other formulations of bupivacaine within 96 hours after administration of bupivacaine liposome.<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930031-s-10","title":"Monitoring","mono":"<ul><li>adequate postsurgical analgesia is indicative of efficacy<\/li><li>cardiovascular vital signs; continuously during and after each injection<\/li><li>neurological status; continuously during and after each injection<\/li><li>respiratory vital signs; continuously during and after each injection<\/li><li>state of consciousness; after each injection<\/li><\/ul>"},"11":{"id":"930031-s-11","title":"How Supplied","mono":"<b>Exparel<\/b><br\/>Injection Suspension: 1.3 %<br\/>"},"13":{"id":"930031-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report signs\/symptoms of arrhythmias (eg, tachycardia, bradycardia).<\/li><li>Instruct patient to report signs\/symptoms of CNS excitation (eg, restlessness, anxiety, tremors) or CNS depression.<\/li><li>Warn patient that drug may cause temporary loss of sensation or motor activity in the infiltrated area.<\/li><li>Drug may cause nausea, constipation, vomiting, dizziness, somnolence, hypotension, and muscle spasms.<\/li><\/ul>"}}}